ALSO NOTED: Ex-Chinese drug official gets 15 years;Sun gets FDA nod for generic dementia drug;

> A former Chinese drug regulator has been sentenced to 15 years in prison for bribery and embezzlement; the harsh punishment is seen as an example of the country's crackdown on food and drug safety. Report

> India's Sun Pharma got the FDA's blessing for its generic version of Exelon, an Alzheimer's and Parkinson's remedy made by Novartis--but won't launch the drug immediately because of outstanding patent litigation. Report

> GlaxoSmithKline has sold 2 million starter kits of its Alli weight-loss product in the five months since it was introduced; the results were in line with company expectations. Report

> A group of researchers are focused on developing a new, nonhormonal contraceptive that uses RNAi technology to silence the ZP3 gene, which is required to fertilize an egg during ovulation. Report

> A molecular mechanism at work during periods of stress may shed light on developing new therapies for post-traumatic stress disorder and other conditions. Report

And Finally... Americans love their sleeping pills, paying $4.5 billion for them annually. But patients think they work better than they really do. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.